NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

促血紅細胞生長素藥的全球市場

Erythropoietin Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 997455
出版日期 內容資訊 英文 182 Pages
商品交期: 最快1-2個工作天內
價格
促血紅細胞生長素藥的全球市場 Erythropoietin Drugs
出版日期: 2021年04月01日內容資訊: 英文 182 Pages
簡介

全球促血紅細胞生長素藥的市場規模,預計在分析期間(2020年∼2027年)將以7.5%的年複合成長率增長,從2020年的115億美元,到2027年達到192億美元。

本報告所分析的市場區隔之一的紅血球生成素Alpha部門,在分析期間中預計將以6.7%的年複合成長率增長,達到79億美元。

本報告提供全球促血紅細胞生長素藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Amgen, Inc.
  • Biocon Ltd.
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Hospira, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • LG Life Sciences India Pvt., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:44公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP11849

Abstract:

Global Erythropoietin Drugs Market to Reach $19.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Erythropoietin Drugs estimated at US$11.5 Billion in the year 2020, is projected to reach a revised size of US$19.2 Billion by 2027, growing at a CAGR of 7.5% over the analysis period 2020-2027. Epoetin-alfa, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$7.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Epoetin-beta segment is readjusted to a revised 7.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.4 Billion, While China is Forecast to Grow at 7.1% CAGR

The Erythropoietin Drugs market in the U.S. is estimated at US$3.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2027 trailing a CAGR of 7.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 6.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Darbepoetin-alfa Segment to Record 8.1% CAGR

In the global Darbepoetin-alfa segment, USA, Canada, Japan, China and Europe will drive the 8.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.9 Billion in the year 2020 will reach a projected size of US$3.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.2 Billion by the year 2027.

Select Competitors (Total 44 Featured) -

  • Amgen, Inc.
  • Biocon Ltd.
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Hospira, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • LG Life Sciences India Pvt., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Epoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Epoetin-beta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Darbepoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Kidney Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 37: Japan Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 40: Japan Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 43: China Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 46: China Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 49: Europe Current & Future Analysis for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 58: France Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 61: France Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 64: Germany Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 67: Germany Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 70: Italy Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 73: Italy Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 76: UK Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 79: UK Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 85: Rest of Europe Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 88: Asia-Pacific Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 91: Asia-Pacific Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 94: Rest of World Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Drug Types for the Years 2012, 2020 & 2027
    • TABLE 97: Rest of World Current & Future Analysis for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of World Historic Review for Erythropoietin Drugs by Application - Anemia, Kidney Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of World 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Anemia, Kidney Disorders and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44